DRUG FACTS
Adults and children 5 years of age and over:
- - Instill 1 drop in the affected eye(s) every 6-8 hours
- - Do not use more than 4 times daily
- - Remove contact lenses before use
- - Wait at least 10 minutes before re-inserting contact lenses after use
- - If using other ophthalmic products while using this product wait at least 5 minutes between each product
- - To avoid contamination, do not touch tip of container to any surface
- - Replace cap after each use
- - Children under 5 years of age: consult a doctor
Active ingredient: Brimonidine tartrate (0.025%) - redness reliever
Purpose: redness reliever
Inactive ingredients: Benzalkonium chloride, boric acid, calcium chloride dihydrate, glycerin, potassium chloride, sodium borate decahydrate, sodium chloride, water for injection. Hydrochloric acid and/or sodium hydroxide may be used to adjust pH.
Store at 15° -25°C (59° -77°F)
Questions or comments?: Call 1-800-553-5340
For external use only
Do not use: if solution changes color or becomes cloudy
Stop use and ask a doctor if:
- - you experience eye pain, changes in vision, continued redness or irritation of the eye
- - condition worsens or persists for more than 3 days
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children.
If swallowed, get medical help or contact a Poison Control Center right away.
FAST-ACTING AND LONG-LASTING EFFICACY1
LUMIFY is so effective at reducing redness, your patients can see the difference almost immediately.*
95% Reported significant improvement in just one minute†
79% Maintained significant redness reduction at eight hours†
*Simulation to reflect average clinical trial results.
†Based on patient reported findings from Phase 3.
Representative of mean pre-instillation score: 1.8
Representative of mean 5 minute post-instillation: 0.5
*Simulation to reflect average clinical trial results.
†Based on patient reported findings from Phase 3.
LOW-RISK FOR TACHYPHYLAXIS
OR REBOUND HYPEREMIA1
Phase III efficacy study2
Overall, six clinical studies were conducted in over 600 patients to evaluate safety and efficacy, with no evidence of allergic reactions reported.
1McLaurin E, Cavet ME, Gomes PJ, Ciolini JB. Brimonidine ophthalmic solution, 0.025% for reduction of ocular redness. Optom Vis Sci. 2018, in press. One reported case of rebound hyperemia in Phase III Safety Study. 2Phase III was a double-blinded, randomized, placebo controlled study. n=60.
FOR YOUR PATIENTS
We’ve provided these videos to help your patients to learn more about LUMIFY.
